Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled adjunctive ganaxolone study in children and adolescents with CDKL5 deficiency disorder
MOH_2019-01-17_003673Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- Jan 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in CDKL5 deficiency disorder (CDD) comparing Ganaxolone with Placebo (2 arms). Primary endpoint: Seizure reduction. Started Jan 2019; status: completed.
02
Drugs
ganaxolone
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on MOH_2019-01-17_003673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-17_003673.